Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109308 | 0.88 | ALDH1A1 (0.61) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL9576615 | 0.85 | ADRB2 (0.61) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL28280197 | 0.84 | ADRB2 (0.56) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL3864388 | 0.83 | ALDH1A1 (0.50) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL9576607 | 0.83 | ADRB2 (0.58) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL6057072 | 0.82 | ADRB2 (0.66) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL163932 | 0.82 | ADRB2 (0.60) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL5164967 | 0.82 | ALDH1A1 (0.54) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL163931 | 0.82 | ALDH1A1 (0.54) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL10455395 | 0.82 | ALDH1A1 (0.54) | ADRB2ADRB1ADRB3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-4886813-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4379819-A | OIL SOLUBLE MONOAZO DYE | CIBA-GEIGY AG (CH) | 1983-04-12 | — | — | US | disclosed |
| US-4080322-A | WATER SOLUBLE DYES FOR LEATHER, PAPER, AND NON-WOVEN TEXTILES | SANDOZ LTD. (CH) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ADRB2 4048/4885ADRB1 3597/4885ADRB3 1196/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ADRB2 4048/4885ADRB1 3597/4885ADRB3 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.